Dr Fred Cohen: Higher Temperatures Trigger Migraines According to New Study

It is only the first full week of summer, and a record-breaking heatwave is already sending temperatures soaring to dangerously high levels in the Northeast and Midwest, with much of the U.S. suffering through sweltering humidity. One medical researcher is cautioning people to watch for headache and migraine attacks as a result. Specifically, Dr Fred Cohen, Assistant Professor of Medicine and Neurology at the Icahn School of Medicine at Mount Sinai in New York, recently co-authored a new headache study that he presented at the American Headache Society’s 66th Annual Scientific Meeting in San Diego, CA, which demonstrates a relationship between weather variables and headache attacks in individuals with migraines.

The Annual Scientific Meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain.

“Many triggers are associated with headaches and migraines, but weather changes are among the most commonly reported; however, data and metrics on these weather changes have rarely been published until now,” said Dr. Cohen. “Our groundbreaking study finds that increased temperature, humidity, and barometric pressure typically intensifies headache attacks in the 40 million Americans who suffer from migraines.”

In the study, researchers examined 71,030 daily diary records from 660 migraine patients and correlated them with regional weather data. They discovered that for each 10-degree Fahrenheit rise in daily temperature, there was a 6% increase in headache occurrences.

Dr Fred Cohen notes that there is hope on the horizon as the study also indicates that patients who were treated with Fremanezumab (Ajovy®), a calcitonin gene-related peptide (CGRP) monoclonal antibody treatment approved by the FDA for migraine prevention, improved these weather-related headaches.

“This study is the first to suggest that migraine-specific therapies that block CGRP may treat weather associated headaches,” adds Dr. Cohen. “It’s quite remarkable that, despite the diverse weather patterns nationwide, we were able to identify such a significant influence. It also raises concerns about greater weather variability and more frequent severe weather events and their relationship with migraines, especially as climate change progresses.”

Another keynote theme of the conference was the use of artificial intelligence (AI) in headache diagnosis, management, and detecting migraine comorbidities. Dr. Cohen gave a lecture on the use of large language models (LLMs), such as ChatGPT and CoPilot, in clinical practice and their potential to improve provider efficiency. Other emerging topics included new acute treatments for migraine, such as vaporized cannabis and novel targets like transient receptor potential melastatin 3 (TRPM3) and pituitary adenylate cyclase-activating polypeptide (PACAP).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”